All News

February 27 2024

NRG Oncology Announces New Leadership of Canadian Members Subcommittee

Read more

February 22 2024

Seeking Applications for BIQSFP Funding for Non-real Time Integrated Studies for NCTN & NCORP Trials

Read more

February 12 2024

NRG Oncology seeks to fill the position of Chair, NRG Oncology NCORP Cancer Prevention Committee

Read more

February 12 2024

Legacy of Dr. Edith Mitchell

Read more

February 12 2024

Protocol Support Committee Column: Addressing Diversity in Clinical Trials

Read more

February 12 2024

Trial Adding Relatlimab to Immunotherapy for Recurrent or Metastatic Nasopharyngeal Cancer Activates (NRG-HN011)

Read more

February 12 2024

NRG Activates Phase II Study for AR-Positive Ovarian Granulosa Cell Tumors (NRG-GY033)

Read more

February 12 2024

FORTE: National Cancer Prevention Month 2024

Read more

February 12 2024

PI Interview: The NRG-CC010 Study for SLN Mapping on Patient-Reported Lower Extremity Limb Dysfunction in Endometrial Cancer

Read more

February 12 2024

PI Interview: The NRG-CC008 (SOROCk) Study Comparing Two Surgical Procedures for Women with BRCA1 Mutations to Assess Risk Reduction for Ovarian Cancer

Read more

February 06 2024

NRG Oncology and the University of Pittsburgh demonstrate that a Machine Learning Model Predicts Oxaliplatin Benefit Using Data from Two NSABP Clinical Trials

Read more

February 02 2024

NRG Oncology Selects Health Equity Fellows for 2024

Read more

January 26 2024

Accepting Applications for Vice Chair, NRG Radiation Oncology Committee

Read more

January 17 2024

A Message from the Chairs of NRG Oncology’s Research Strategy Committee

2023: The Year in Review Read more

January 17 2024

The FORTE Workshop is coming soon…

Read more

January 17 2024

PSC Continuing Education Sessions at #NRG2024

Read more

January 17 2024

Cervical Cancer Awareness Month

2023 Cervical Highlights Read more

January 17 2024

Annual Message from the NRG Oncology Group Chairs

Read more

December 15 2023

NRG Oncology seeks to fill the position of Chair, NRG Oncology Canadian Members Subcommittee

Read more

December 11 2023

Managing Data and Query Expectation in NCI Research Studies

Read more

December 11 2023

The “High Five Trial” for High-Risk Prostate Cancer Activates (NRG-GU013)

Read more

December 11 2023

NRG PCOR Educational Session at #NRG2024 in Orlando

Read more

December 11 2023

Honoring a Legacy: Dr. Worta McCaskill-Stevens

Read more

December 05 2023

NRG-BR008, HERO Study Seeks to Optimize use of Radiotherapy in Patients with Early-Stage, Low Risk, HER2-Positive Breast Cancer

Read more

November 14 2023

ADVERSE EVENT REPORTING: One site’s use of EMR functionality to establish Best Practice

Read more

November 14 2023

FORTE Study Update - November 2023

Read more

November 14 2023

Pancreatic Cancer Awareness Month

Updates from the NRG Oncology Pancreatic Cancer Working Group Read more

November 14 2023

National Family Caregivers Month

The Caregiver Experience with Clinical Trials: Understanding the Emotions and Clarifying the Details for Patients Read more

November 09 2023

FORTE, a Colorectal Cancer Prevention Clinical Trial, accrues its first 1,000 participants

Read more

October 24 2023

New Vice Chair named for NRG Health Disparities Committee (HDC)

Dr. Evan Graboyes named HDC Vice Chair, effective immediately Read more

October 17 2023

FORTE Study Update - October 2023

Read more

October 17 2023

Informed Consent Guidance Now Available

Read more

October 17 2023

Megan Mullins, PhD, NRG Cancer Care Delivery Researcher, Examines Health Equity Issues in Latest Publication

Read more

October 17 2023

NRG-BR009 (“OFSET”): A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression and Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score of ≤ 25

Read more

October 03 2023

RTOG 1308 Accrual Completion: First Phase III NCTN Clinical Trial Comparing Photon Versus Proton Therapy to Meet Accrual Target

Read more

September 14 2023

FORTE Study Update - September 2023

Read more

September 14 2023

Pharmaceutical Management Branch (PMB) AURORA Updates

Read more

September 14 2023

Reminder to review CTEP IAM account and NRG roster status

Read more

September 12 2023

Secondary Analysis of NRG Oncology-RTOG 0617 Presented at IASLC 2023

Read more

August 14 2023

NRG Oncology PSC 2023 Summer Meeting Wrap Up

Read more

August 14 2023

FORTE Study Update - August 2023

Read more

July 21 2023

NRG Oncology Honors Dr. Walter ‘Wally’ Curran as First NRG Oncology Gold Medalist

Read more

July 21 2023

NRG Oncology Announces New Leadership of the Organization’s Cancer Prevention & Control Committee, Immunotherapy Subcommittee, and Publications Committee

Read more

July 17 2023

FORTE Study Update - July 2023

Read more

July 17 2023

Life as an Adolescent Young Adult Cancer Survivor

Read more

July 06 2023

NRG Oncology seeks to fill the position of Vice-Chair, NRG Oncology NCORP Health Disparities Research Committee

Read more

June 15 2023

Addition of EBRT to Brachytherapy Did Not Improve Outcomes for Men with Intermediate-Risk Prostate Cancer, Brachytherapy Alone Remains Standard of Care

Read more

June 09 2023

PSC at the NRG 2023 Summer Meeting

Read more

June 09 2023

FORTE Study Update: June 2023

Read more

June 09 2023

NRG Oncology Awards 11 Fellows for the Early Career & New Investigator Mentored Fellowship Program

Read more

June 09 2023

Comparing Stereotactic Radiosurgery to Hippocampal-Avoidant Whole Brain Radiotherapy for Patients with High Brain Metastasis Velocity at Distant Brain Relapse Following Stereotactic Radiosurgery (NRG-BN009)

Read more

June 09 2023

SBRT to the Primary Tumor Followed by Conventional Radiation Therapy and Chemotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer (NRG-LU008)

Read more

June 09 2023

Breaking Impossible

Read more

June 01 2023

Through a joint project and on common ground, a large number of investigators from US trial groups and the National Cancer Institute reached consensus on issues regarding the strength of pre-clinical data and study designs via extensive interactions

Read more

May 10 2023

Introducing SDMC Statistics Division Member, Eric Polley, Ph.D.

Read more

May 10 2023

Spotlight on the PSC Working Groups

Read more

May 10 2023

FORTE Study Update: May 2023

Read more

May 10 2023

Not Leaving Veterans Behind

Read more

May 10 2023

Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer (NRG-CC009)

Read more

May 10 2023

Should SRS be Delivered Before or After Surgery for Patients with Brain Metastases? (NRG-BN012)

Read more

April 28 2023

NRG Oncology Seeks to Fill the Position of Vice-Chair, NRG Oncology NCORP Cancer Control Committee

Read more

April 27 2023

Patient-Reported Outcomes from an NRG Oncology Study of Androgen Deprivation Therapy with Dose-Escalated Radiotherapy for Intermediate-Risk Prostate Cancer Show No Clinically Meaningful Differences in Scores at One Year Post-Treatment

Read more

April 27 2023

NRG Oncology Trial Does Not Improve Overall Survival, but Shows Improvements in Several Clinical Outcomes for Men with Intermediate-Risk Prostate Cancer

Read more

April 27 2023

NRG Oncology Study Results Confirm Conventional External Beam Radiotherapy Should Remain Standard of Care in Treating Localized Vertebral Metastases of the Spine

Read more

April 18 2023

Webinar: NRG-GI004 / SWOG S1610 COMMIT Study Amendment 9 Overview

Read more

April 12 2023

Show Me the Money

Read more

April 12 2023

FORTE at #NRG2023!

Read more

April 12 2023

Comparing Selumetinib and Olaparib to Selumetinib Alone for Ovarian and Endometrial Cancers with RAS Pathway Mutations (EAY191-N4, A ComboMATCH Treatment Trial)

Read more

April 12 2023

Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone-Receptor Positive Metastatic Breast Cancer (EAY191-N2, A ComboMATCH Treatment Trial)

Read more

April 12 2023

WVOCA Donates Additional Funds to the NRG Oncology Health Equity Fellowship Program

Read more

April 12 2023

PI Perspective: The Journey of NRG-GY018

Read more

April 12 2023

NRG Oncology and RTOG Foundation Integrated Efforts in the Head and Neck Cancer Committee

Read more

April 12 2023

Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable HER2-positive Salivary Gland Cancer (NRG-HN010)

Read more

April 06 2023

Webinar: Surgical Implications of ctDNA: Is this the future for colon cancer?

Read more

March 31 2023

NRG Oncology Combined Trial Long-Term Results Indicate that Pathologic Complete Response is Prognostic of Outcomes for Soft Tissue Sarcoma Patients

Read more

March 27 2023

Late-Breaking Results of NRG-GY018 Presented at SGO 2023: Study Demonstrates Improved PFS Outcomes with the Addition of Pembrolizumab to Chemotherapy for Women with Advanced or Recurrent Endometrial Cancer

Read more

March 26 2023

Study Identifies Two Promising Molecular Targets for Drug Development in Recurrent and Metastatic Cervical Cancer

Read more

March 25 2023

The Utilization of Atezolizumab as a Primer for Chemoradiation Results in Promising Immune System Alterations for Women with Locally Advanced Cervical Cancer

Read more

March 25 2023

The Addition of Gemcitabine with Cisplatin and Intensity-Modulated Radiation Therapy Improves Outcomes for Women with Locally Advanced Vulvar Cancer

Read more

March 15 2023

Circulating Tumor DNA: One of Our Newest Tools for Managing Solid Tumors

Read more

March 15 2023

NRG-BR008 (“HERO”): A Phase III Randomized Trial Seeking to Optimize Use of Radiotherapy in Patients with Early-Stage, Low Risk, HER2-Positive Breast Cancer

Read more

March 15 2023

FORTE Study News: It’s Colorectal Cancer Awareness Month!

Read more

March 09 2023

RFAs for the NRG Early Career & New Investigators (ECNI) Committee AND for the NRG ECNI Mentored Fellowship

Read more

February 16 2023

NRG NCORP Solicits PILOT Projects for NRG NCORP Health Disparities Research (HDR) Priorities

Read more

February 15 2023

NRG Oncology seeks to fill the position of Chair of the NRG Oncology Publications Committee

Read more

February 15 2023

NRG Oncology seeks to fill the position of Vice-Chair, NRG Oncology Immunotherapy Subcommittee

Read more

February 15 2023

NRG NCORP Solicits PILOT Projects for NRG NCORP Cancer Prevention Control (CPC) Priorities

Read more

February 15 2023

NRG NCORP Solicits PILOT Projects for NRG NCORP Cancer Care Delivery Research (CCDR) Priorities

Read more

February 14 2023

Protocol Support Committee (PSC) Column: NRG Oncology PSC 2023 Winter Meeting Wrap Up

Read more

February 14 2023

Initial Report on Establishing Working Groups within the Head and Neck Cancer Committee

Read more

February 14 2023

FORTE Study Update: Participant Travel Allowance

Read more

February 09 2023

NRG Oncology Selects Three Awardees for Health Equity Fellowship Program

Read more

February 03 2023

NRG Oncology NRG-GY018 Study Demonstrates Significantly Improved Progression Free Survival Outcomes for Women with Advanced or Recurrent Endometrial Cancer with the Addition of Pembrolizumab to Chemotherapy

Read more

January 18 2023

Set Up for Success - Coordinating RECIST 1.1: A Community Hospital Perspective

Read more

January 18 2023

#FORTEStudy Workshop

Read more

January 18 2023

NRG Innovations Continue in Cancer Care Delivery Research

Read more

January 18 2023

Adding Atezolizumab to Cisplatin and Radiotherapy for Node-Positive Locally Advanced Cervical Cancer (NRG-GY017)

Read more

January 18 2023

A Message from the NRG Oncology Research Strategy Committee Chairs: 2022: The Year in Review

Read more

January 18 2023

A Message from the NRG Oncology Group Chairs: 2022 in Review and a Look Ahead

Read more

December 19 2022

NRG Oncology Holiday Closures for 2022

Read more

December 12 2022

NRG Meeting PSC Information

Read more

December 12 2022

NRG-CC005/FORTE Site Implementation Guide: Part 1

Read more

December 12 2022

Julian Hong, M.D., M.S.: Steward of Cancer Care Delivery Research and Innovation

Read more

December 12 2022

NRG Oncology Announces Leadership of New Diversity, Equity, and Inclusion Committee, New Vice Chair for Ancillary Projects Committee

Read more

November 09 2022

Protocol Support Committee Column: NRG Best Practice Tool

Read more

November 09 2022

Dr. Jong H. Jeong Joins NRG Oncology SDMC

Read more

November 09 2022

#FORTEStudy is on YouTube!

Read more

November 09 2022

Assessing SBRT to the Primary Tumor Followed by Conventional Radiation Therapy with Concurrent Chemotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer (NRG-LU008)

Read more

November 09 2022

Assessing the Addition of IMPRINT to Surgery and Systemic Therapy for Malignant Pleural Mesothelioma (NRG-LU006)

Read more

November 03 2022

NRG Oncology Patient Advocate Committee - Call for Candidates

Read more

October 24 2022

Multi-Modal Artificial Intelligence Models Offer a More Accurate Prognostication Method for Intermediate- to High-Risk Localized Prostate Cancer than Current NCCN Standard

Read more

October 24 2022

NRG Oncology Trial NRG-HN004 Shows Addition of Durvalumab to Radiation Does Not Improve Outcomes over Cetuximab for Head & Neck Squamous Cell Carcinoma Patients with a Contraindication to Cisplatin, Highlights Need for Further Research

Read more

October 24 2022

Three Week Hypo-fractionated Whole Breast Irradiation (WBI) with Concurrent Boost is not Inferior to Conventional WBI with a Sequential Boost Following Lumpectomy for Patients with High-Risk, Early-Stage Breast Cancer

Read more

October 24 2022

The Addition of Stereotactic Body Radiation Therapy (SBRT) to Sorafenib in Patients with Advanced Hepatocellular Carcinoma Improves Overall Survival

Read more

October 12 2022

The Protocol Support Committee (PSC) Wants You!

Read more

October 12 2022

#FORTEStudy in Chicago!

Read more

October 12 2022

Comparing Docetaxel and Trastuzumab to Ado-Trastuzumab Emtansine for HER2-positive Salivary Gland Cancer (NRG-HN010)

Read more

October 12 2022

Assessing the Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Endometrial Cancer (NRG-CC010)

Read more

October 12 2022

NRG-BR008 (“HERO”): A Phase III Randomized Trial Seeking to Optimize Use of Radiotherapy in Patients with Early-Stage, Low Risk, HER2-Positive Breast Cancer

Read more

October 12 2022

NRG-BR007 (“DEBRA”): A Phase III Clinical Trial Evaluating the De-escalation of Breast Radiation for a More Conservative Treatment of Patients With Low-Risk, Hormone-Sensitive, Node-Negative Breast Cancer

Read more

October 06 2022

NRG Oncology Appoints Chair & Vice Chair of Radiation Oncology Committee

Read more

September 26 2022

Foundation Accrual Credit for NRG Membership Requirements Announcement

Read more

September 21 2022

Intensity Modulated Radiotherapy Improved Patient-Reported Outcomes on NRG Oncology Clinical Trial

Read more

September 15 2022

In Memoriam: James Lloyd Hoehn, MD, FACS

Read more

September 15 2022

Protocol Committee Support (PSC) Column: No Surprises Billing Act 2022

Read more

September 15 2022

NRG Health Equity Fellowship Call for Applications

Read more

September 15 2022

Comparing the Addition of Radiation before or After Surgery for Patients with Brain Metastases (NRG-BN012)

Read more

September 15 2022

Comparing Every Three Week Versus Weekly Cisplatin with Radiotherapy for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (NRG-HN009)

Read more

September 15 2022

NRG-GU011 (“NRG PROMETHEAN”) study of SABR with or without relugolix for PET-recurrent oligometastatic prostate cancer

Read more

September 15 2022

NRG-GU009 ( “PREDICT-RT”) Parallel Phase III Randomized Trials For High Risk Prostate Cancer Evaluating De-Intensification For Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation

Read more

September 15 2022

Testing the addition of trastuzumab or trastuzumab/pertuzumab to the usual chemotherapy for HER2 positive uterine serous or carcinosarcoma (NRG-GY026)

Read more

September 12 2022

NRG Oncology accepting applications for the position of Vice Chair, Ancillary Projects Committee

Read more

August 18 2022

NRG Oncology and The GOG Foundation Honor the Life of Mary "Dicey" Scroggins

Read more

August 12 2022

Summer Meeting 2022 Protocol Support Committee (PSC) Wrap Up

Read more

August 12 2022

FORTE Study Updates: Natural Language Processing Update

Read more

August 05 2022

NRG Oncology accepting applications for the position of Vice Chair, Radiation Oncology Committee

Read more

July 29 2022

NRG Oncology Trial Aimed to Improve Prostate Cancer Survivor Care Planning Reaches Accrual Goal

Read more

July 27 2022

Oncology Tube Conducts Interviews on NRG Oncology Research Presented During the 2022 ASCO Annual Meeting: NRG-HN002 and NRG-GI008

Read more

July 26 2022

NRG Oncology NCORP Trial of Hippocampal Avoidance for Small Cell Lung Cancer Patients Receiving Prophylactic Cranial Irradiation Reaches Accrual Goal

Read more

July 19 2022

NRG Oncology Appoints Several New Committee Chairs & Vice Chairs

Read more

July 13 2022

Adding Stereotactic Radiation Therapy to Immune Therapy for Patients with Advanced Renal Cell Cancer (NRG-GU012, The “SAMURAI” Study)

Read more

July 13 2022

IACRN: International Association of Clinical Research Nurses

Read more

July 13 2022

NRG NCORP Selects CCDR Pilot Project Awardee

Read more

July 13 2022

Join FORTE at the NRG Oncology Semiannual Meeting!

Read more

July 12 2022

NRG Oncology Accepting Applications for Radiation Oncology Committee Chair Position

Read more

July 08 2022

NRG Oncology Study of Atezolizumab and Chemoradiation for Patients with Limited-Stage Small Cell Lung Cancer Completes Accrual

Read more

June 29 2022

PSA-Based Endpoints Should Not Be Used as Surrogate Endpoints for Overall Survival in Men with Recurrent Prostate Cancer at this Time

Read more

June 28 2022

Joint Final Report of Phase III trials Demonstrate Positive Outcomes from Combination of PCV Chemotherapy and RT in Patients with Anaplastic Oligodendroglial Tumors

Read more

June 27 2022

Additional Taxane Maintenance Therapy Does Not Successfully Improve Overall Survival for Women with Advanced Ovarian, Peritoneal, and Tubal Cancers

Read more

June 08 2022

The Vision of Remote Auditing and Monitoring

Read more

June 08 2022

NRG-CC005 (FORTE) Breaking News! Welcome to the FORTE Education and Communication Specialist

Read more

May 12 2022

NRG Oncology NCORP Accepting Applications for NRG Meeting Travel Awards: Deadline May 26, 2022

Read more

May 11 2022

Preparing for the NRG Quality Assurance Audit

Read more

May 11 2022

FORTE STUDY UPDATE: NRG-CC005/FORTE Trial Communications

Read more

May 11 2022

A Randomized Phase II Trial of Immunotherapy with Dual Immune Checkpoint Inhibitors Compared to Anti-PD1 Monotherapy in Patients with Deficient Mismatch Repair System Recurrent Endometrial Carcinoma (NRG-GY025)

Read more

May 11 2022

A Study Champion Perspective: Christina Henson, MD

Read more

May 11 2022

Upcoming Trial Highlight: Studying Stereotactic Radiosurgery Before Versus After Surgery for Patients with Resectable Brain Metastases (NRG-BN012)

Read more

May 11 2022

NRG-BN011 Seeks to Improve Treatment Outcomes in a Substantial Subset of Glioblastoma Patients with Dual Alkylating Therapy

Read more

May 11 2022

A Safety Run-in and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma (NRG-BN010)

Read more

May 09 2022

NRG Oncology Study of Photon Versus Proton Therapy for Patients with Newly Diagnosed Glioblastoma Completes Accrual

Read more

May 09 2022

NRG Oncology Board of Directors Member, Dr. Priya Rastogi named NSABP Foundation CEO

Read more

April 29 2022

NRG Oncology Executive Director is Stepping Down from the Position

Read more

April 29 2022

NRG NCORP is Soliciting PILOT Projects Focused on Biospecimens and Clinical Trial Data: Breast Cancer Prevention Studies

Read more

April 29 2022

DEADLINE APRIL 29TH: NRG Oncology seeks to fill the position of Chair, NRG Oncology Surgical Oncology Committee

Read more

April 19 2022

West Valley Ovarian Cancer Alliance Gifts Generous Donation to the NRG Oncology Under-Represented Minority Investigator Program

Read more

April 13 2022

DEADLINE EXTENDED: NRG Oncology seeks to fill the position of Chair, NRG Oncology Immunotherapy Subcommittee

Read more

April 12 2022

FORTE STUDY UPDATE: NRG-CC005 (The FORTE Study)

Read more

April 12 2022

Testing ctDNA as a Biomarker for Adjuvant Therapy Intensity in Stage 3 Colon Cancer (NRG-GI008, The “CIRCULATE-US” Study)

Read more

April 12 2022

April is National Cancer Control Month: NRG Protocol Support Committee Column

Read more

April 12 2022

Exploring Options to Potentially Improve Treatment and Quality of Life for Patients in Two Head and Neck Cancer Trials

Read more

April 11 2022

NRG Oncology Announces New Veterans Affairs and Military Treatment Facility Subcommittee, Appoints Subcommittee Chairs

Read more

April 08 2022

NRG Oncology seeks applications for Chair of the NRG Early Career New Investigators Committee

Read more

March 24 2022

Webinar: Implementation Science for Digital Health

Read more

March 18 2022

NRG Oncology Trial Indicates Using Atezolizumab with Chemoradiation is Safe and Demonstrates Signs of Immune Activation in Women with Cervical Cancer

Read more

March 18 2022

HRR Mutational Status Prognostic of Survival Outcomes in Biomarker Analysis of NRG Oncology Trial for Women with Recurrent Platinum-Sensitive Ovarian Cancer

Read more

March 16 2022

OlympiA Trial (NSABP B-55): Olaparib as adjuvant treatment reduces risk of death by 32% in patients with germline BRCA mutations and high-risk early breast cancer

Read more

March 10 2022

NRG Oncology seeks to fill the position of Co-Chair, Patient Centered Outcomes Research Committee

Read more

March 08 2022

NRG Oncology PSC 2022 Winter Meeting Wrap Up

Read more

March 08 2022

Congratulations to the NRG Oncology Members Assigned to NCI Gastrointestinal Task Forces - Rectal/Anal Cancers

Read more

March 08 2022

FORTE Study Update - March NRG Newsletter

Read more

March 08 2022

Coming Attractions or Recent Additions in NRG Colorectal Cancer Research: NRG-GI005

Read more

March 08 2022

Coming Attractions or Recent Additions in NRG Colorectal Cancer Research: NRG-GI008

Read more

March 08 2022

The NRG-GI004/SWOG1610, the COMMIT Study, may further improve outcomes in Metastatic Colorectal Cancer with deficiency of DNA repair (dMMR/MSI- H)

Read more

March 08 2022

Project Team Member Application - CBX-12

Read more

February 18 2022

NRG NCORP Solicits PILOT Projects for NRG NCORP Cancer Care Delivery Research (CCDR) Priorities

Read more

February 18 2022

NRG NCORP Solicits PILOT Projects for NRG NCORP Health Disparities Research (HDR) Priorities

Read more

February 18 2022

NRG NCORP Solicits PILOT Projects for NRG NCORP Cancer Prevention Control (CPC) Priorities

Read more

February 15 2022

2022 Symposium & Workshop: Precision Medicine Applications in Radiation Oncology

Read more

February 11 2022

The Scientific Session - February 2022

Read more

February 09 2022

NRG Oncology Announces First Participant Enrolled on FORTE NRG-CC005

Read more

February 08 2022

Dr. Miller Re-elected as Biostatistician for the NCI Uterine Task Force

Read more

February 08 2022

RECIST 1.1 Criteria Toolkit: A Resource for Success in Clinical Trials with Solid Tumor Evaluation Requirements

Read more

February 08 2022

NRG-CC008: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]

Read more

February 08 2022

FORTE Study Updates (Feb 2022 Newsletter)

Read more

February 03 2022

NRG Oncology Trial Results Indicate Trametinib Should Represent the New Standard of Care for Women with Recurrent Low-Grade Serous Ovarian Cancer

Read more

January 21 2022

Trastuzumab with Chemoradiation and Surgery Does Not Improve Outcomes for Esophageal Cancer Patients, Trial Highlights Future Research Opportunities

Read more

January 12 2022

It’s All in the DETAILS!

Read more

January 12 2022

Moving Research Forward through Legislative Advocacy

Read more

January 12 2022

De-intensification and Intensification Treatments for High-Risk Prostate Cancer Patients Stratified by Genomic Risk (NRG-GU009, the “PREDICT-RT” Trial)

Read more

January 12 2022

Phase 2 Double-Blinded Trial Combining Oligometastatic Radiotherapy with Androgen Deprivation Therapy (NRG-GU011)

Read more

Stay current with science. Sign up for our newsletter.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.